Aktiedagen Stockholm – May 2, 2022

Sedermeradagen – April 25, 2022

AP1189

A Novel and First-in-Class Agent to Target the Melanocortin System

Our drug candidate AP1189, a once-daily oral selective melanocortin agonist, specifically stimulates melanocortin receptors to help the body resolve inflammation. SynAct is currently evaluating AP1189 in rheumatoid arthritis (RA), in idiopathic membranous nephropathy (iMN, an autoimmune disease associated with the development of nephrotic syndrome) and in the treatment of respiratory insufficiency caused by viruses like COVID-19.

A MESSAGE FROM OUR CEO

”SynAct is in a strong financial position with a strong pipeline, and we are all grateful for the support and look forward to the second half of the year.”